Decipher Labs Ltd
Incorporated in 1986, Decipher Labs Ltd deals in trading and manufacturing of Pharmaceutical drugs and provides services and key solutions in Information Technology.
- Market Cap ₹ 15.2 Cr.
- Current Price ₹ 15.1
- High / Low ₹ 25.8 / 14.4
- Stock P/E 508
- Book Value ₹ 8.65
- Dividend Yield 0.00 %
- ROCE 0.34 %
- ROE 0.22 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company's working capital requirements have reduced from 312 days to 11.4 days
Cons
- Promoter holding is low: 16.4%
- Company has a low return on equity of 0.23% over last 3 years.
- Company has high debtors of 408 days.
- Promoter holding has decreased over last 3 years: -29.5%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.50 | 0.05 | 0.10 | 0.22 | 0.38 | 1.02 | 6.78 | 1.42 | 0.98 | 0.99 | 0.81 | 3.53 | 3.99 | |
0.48 | 0.38 | 0.29 | 0.80 | 0.56 | 0.95 | 6.41 | 1.26 | 0.96 | 0.63 | 1.11 | 3.51 | 3.96 | |
Operating Profit | 0.02 | -0.33 | -0.19 | -0.58 | -0.18 | 0.07 | 0.37 | 0.16 | 0.02 | 0.36 | -0.30 | 0.02 | 0.03 |
OPM % | 4.00% | -660.00% | -190.00% | -263.64% | -47.37% | 6.86% | 5.46% | 11.27% | 2.04% | 36.36% | -37.04% | 0.57% | 0.75% |
0.05 | -0.26 | -3.26 | -0.61 | 0.00 | 0.11 | 0.01 | 0.01 | 0.14 | 0.05 | -2.28 | 0.02 | 0.03 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.21 | 0.21 | 0.23 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.06 | 0.01 | 0.00 |
Profit before tax | -0.14 | -0.80 | -3.68 | -1.28 | -0.18 | 0.18 | 0.38 | 0.17 | 0.10 | 0.36 | -2.64 | 0.03 | 0.06 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.76% | 0.00% | |
-0.14 | -0.80 | -3.68 | -1.28 | -0.18 | 0.18 | 0.38 | 0.17 | 0.10 | 0.36 | -2.62 | 0.02 | 0.03 | |
EPS in Rs | -0.18 | -1.00 | -4.60 | -1.60 | -0.22 | 0.22 | 0.48 | 0.17 | 0.10 | 0.36 | -2.59 | 0.02 | 0.03 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 53% |
5 Years: | -12% |
3 Years: | 53% |
TTM: | 2394% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | -45% |
3 Years: | -42% |
TTM: | 105% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | -10% |
3 Years: | -31% |
1 Year: | -11% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | 1% |
3 Years: | 0% |
Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
Reserves | -0.14 | -0.92 | -4.60 | -5.88 | -6.06 | -5.88 | -5.50 | 0.97 | 1.06 | 1.42 | -1.20 | -1.17 | -1.36 |
0.05 | 0.05 | 0.00 | 0.00 | 0.05 | 0.13 | 0.14 | 0.23 | 0.14 | 0.00 | 0.00 | 0.00 | 0.16 | |
0.77 | 0.80 | 0.45 | 0.49 | 0.59 | 0.71 | 3.20 | 0.35 | 0.10 | 0.08 | 0.09 | 3.83 | 0.20 | |
Total Liabilities | 8.68 | 7.93 | 3.85 | 2.61 | 2.58 | 2.96 | 5.84 | 11.65 | 11.40 | 11.60 | 8.99 | 12.76 | 9.10 |
4.27 | 4.06 | 0.86 | 0.00 | 0.00 | 0.00 | 0.01 | 0.11 | 0.26 | 0.33 | 0.12 | 0.10 | 0.15 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 8.41 | 8.41 | 8.66 | 8.66 | 8.66 | 8.66 |
4.41 | 3.87 | 2.99 | 2.61 | 2.58 | 2.96 | 5.78 | 3.13 | 2.73 | 2.61 | 0.21 | 4.00 | 0.29 | |
Total Assets | 8.68 | 7.93 | 3.85 | 2.61 | 2.58 | 2.96 | 5.84 | 11.65 | 11.40 | 11.60 | 8.99 | 12.76 | 9.10 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.09 | 0.00 | 0.10 | -0.25 | -0.02 | -0.10 | 0.04 | -0.01 | 0.27 | 0.55 | -0.08 | -0.03 | |
0.00 | 0.00 | 0.00 | 0.16 | 0.00 | 0.00 | -0.05 | -0.07 | -0.19 | -0.38 | 0.09 | 0.00 | |
-0.01 | 0.00 | 0.00 | 0.00 | 0.05 | 0.09 | 0.01 | 0.09 | -0.09 | -0.14 | 0.00 | 0.00 | |
Net Cash Flow | -0.10 | 0.00 | 0.10 | -0.09 | 0.03 | -0.01 | -0.01 | 0.01 | -0.01 | 0.03 | 0.01 | -0.03 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 430.70 | 2,701.00 | 292.00 | 116.14 | 134.47 | 211.13 | 163.66 | 43.70 | 152.70 | 81.11 | 58.58 | 408.43 |
Inventory Days | 1,856.74 | 2,027.78 | 696.82 | 98.27 | 91.25 | 19.70 | 188.39 | 34.76 | 91.25 | 0.00 | 0.00 | |
Days Payable | 936.30 | 1,013.89 | 1,294.09 | 645.77 | 511.00 | 192.66 | 135.40 | 0.00 | 0.00 | |||
Cash Conversion Cycle | 1,351.13 | 2,701.00 | 1,305.89 | -481.14 | -413.03 | -208.62 | -9.30 | 96.68 | 187.47 | 172.36 | 58.58 | 408.43 |
Working Capital Days | 1,043.90 | 6,278.00 | 839.50 | -165.91 | -259.34 | 797.99 | 137.82 | 706.87 | 975.82 | 910.66 | 13.52 | 11.37 |
ROCE % | -1.75% | -6.78% | -6.27% | -23.91% | -8.76% | 8.49% | 15.54% | 2.44% | 1.06% | 3.16% | -3.23% | 0.34% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting For The Quarter 30.09.2024 Under Regulation 30 And 33 Of SEBI (LODR) Regulations, 2015.
14 Nov - Board approved unaudited financial results for Q2 2024.
- Unaudited Financial (Standalone And Consolidated) Results For The Quarter And Half Year Ended 30.09.2024 14 Nov
-
Board Meeting Intimation for Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2024.
8 Nov - Board meeting on November 14 to discuss financial results.
-
Compliance As Per Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018 For The Quarter Ended September 30, 2024.
17 Oct - Compliance with SEBI regulations for dematerialization.
-
Closure of Trading Window
30 Sep - Closure of trading window until financial results announcement.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Services Offered:[1][2]
a) Pharmaceuticals: Manufacturing & Marketing of Branded Formulations and Custom Manufacturing for companies. Company also caters to various formulators, manufacturers and Research and Development agencies for their Bulk needs and sources and supplies various drugs and allied products & services to companies upon request.
b) Information Technology: Company has taken over Decipher Software Solutions LLC in USA which is an Information Technology services firm, specializing in ERP Implementation, Mobile & Cloud solutions, Product Development, Offshore Services, Technology Integration and Systems Consulting, Software Development Consulting and Management of IT projects.